WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317510
CAS#: 118-42-3 (free base)
Description: Hydroxychloroquine is an autophagy inhibitor. It acts by inducing apoptosis of renal cancer cells in vitro and inhibiting TLR9. Hydroxychloroquine (HCQ) is a medication used to prevent and treat malaria in areas where malaria remains sensitive to chloroquine. Other uses include treatment of rheumatoid arthritis, lupus, and porphyria cutanea tarda. It is taken by mouth. It is also being studied as an experimental treatment for coronavirus disease 2019 (COVID-19).
Hodoodo Cat#: H317510
Name: Hydroxychloroquine free base
CAS#: 118-42-3 (free base)
Chemical Formula: C18H26ClN3O
Exact Mass: 335.18
Molecular Weight: 335.876
Elemental Analysis: C, 64.37; H, 7.80; Cl, 10.55; N, 12.51; O, 4.76
Related CAS #: 118-42-3 (free base) 747-36-4 (sulfate) 6168-85-0 (phosphate) 137433-23-9 (R-free) 137433-24-0 (S-free)
Synonym: Hydrochloroquine; Ercoquin; Plaquinol; Toremonil; Oxychlorochin; Oxychloroquine; Plaquenil; WIN 1258; Z0188;
IUPAC/Chemical Name: 2-((4-((7-chloroquinolin-4-yl)amino)pentyl)(ethyl)amino)ethan-1-ol
InChi Key: XXSMGPRMXLTPCZ-UHFFFAOYSA-N
InChi Code: InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)
SMILES Code: OCCN(CCCC(NC1=CC=NC2=CC(Cl)=CC=C12)C)CC
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 335.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Xie W, Wang Y, Zhang Z. Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality? Ann Rheum Dis. 2020 Apr 21:annrheumdis-2020-217556. doi: 10.1136/annrheumdis-2020-217556. Epub ahead of print. PMID: 32317316.
2: Moiseev S, Avdeev S, Brovko M, Novikov P, Fomin V. Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)? Ann Rheum Dis. 2020 Apr 21:annrheumdis-2020-217570. doi: 10.1136/annrheumdis-2020-217570. Epub ahead of print. PMID: 32317315.
3: Aduriz-Lorenzo PM, Aduriz-Llaneza P, Araiz-Iribarren J, Khamashta MA. Current opinion on hydroxychloroquine-related retinal toxicity screening: where do we stand now? Lupus. 2020 Apr 21:961203320919499. doi: 10.1177/0961203320919499. Epub ahead of print. PMID: 32316844.
4: Sun Y, Zhang J, Li X, Sun E. [Hydroxychloroquine alleviates 5-fluorouracil- induced enteritis in mice and its mechanism]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2020 Jan;36(1):1-8. Chinese. PMID: 32314717.
5: Falcão MB, Pamplona de Góes Cavalcanti L, Filgueiras Filho NM, Antunes de Brito CA. Case Report: Hepatotoxicity Associated with the Use of Hydroxychloroquine in a Patient with Novel Coronavirus Disease (COVID-19). Am J Trop Med Hyg. 2020 Apr 17. doi: 10.4269/ajtmh.20-0276. Epub ahead of print. PMID: 32314698.
6: Lazaros G, Antonopoulos AS, Antonatou K, Skendros P, Ritis K, Hadziyannis E, Lazarou E, Leontsinis I, Simantiris S, Vlachopoulos C, Tousoulis D, Vassilopoulos D. Hydroxychloroquine for colchicine-resistant glucocorticoid- dependent idiopathic recurrent pericarditis: A pilot observational prospective study. Int J Cardiol. 2020 Mar 30:S0167-5273(20)30011-5. doi: 10.1016/j.ijcard.2020.03.069. Epub ahead of print. PMID: 32312616.
7: Rathi S, Ish P, Kalantri A, Kalantri S. Hydroxychloroquine prophylaxis for COVID-19 contacts in India. Lancet Infect Dis. 2020 Apr 17:S1473-3099(20)30313-3. doi: 10.1016/S1473-3099(20)30313-3. Epub ahead of print. PMID: 32311324; PMCID: PMC7164849.
8: Principi N, Esposito S. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis. 2020 Apr 17:S1473-3099(20)30296-6. doi: 10.1016/S1473-3099(20)30296-6. Epub ahead of print. PMID: 32311322; PMCID: PMC7164862.
9: Taccone FS, Gorham J, Vincent JL. Hydroxychloroquine in the management of critically ill patients with COVID-19: the need for an evidence base. Lancet Respir Med. 2020 Apr 15:S2213-2600(20)30172-7. doi: 10.1016/S2213-2600(20)30172-7. Epub ahead of print. PMID: 32304640; PMCID: PMC7159849.
10: Zhu X, Sun J. A case of facial atrophic sarcoidosis in an adolescent, successfully treated by the combination of prednisone and hydroxychloroquine. An Bras Dermatol. 2020 Mar 19:S0365-0596(20)30076-3. doi: 10.1016/j.abd.2019.08.028. Epub ahead of print. PMID: 32299736.
11: Sarma P, Kaur H, Kumar H, Mahendru D, Avti P, Bhattacharyya A, Prajapat M, Shekhar N, Kumar S, Singh R, Singh A, Dhibar DP, Prakash A, Medhi B. Virological and Clinical Cure in Covid-19 Patients Treated with Hydroxychloroquine: A Systematic Review and Meta-Analysis. J Med Virol. 2020 Apr 16. doi: 10.1002/jmv.25898. Epub ahead of print. PMID: 32297988.
12: Costanzo M, De Giglio MAR, Roviello GN. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus. Curr Med Chem. 2020 Apr 16. doi: 10.2174/0929867327666200416131117. Epub ahead of print. PMID: 32297571.
13: Sinha N, Balayla G. Hydroxychloroquine and covid-19. Postgrad Med J. 2020 Apr 15:postgradmedj-2020-137785. doi: 10.1136/postgradmedj-2020-137785. Epub ahead of print. PMID: 32295814.
14: Heldwein FL, Calado A. Does hydroxychloroquine prevent the transmission of covid-19? Ann Rheum Dis. 2020 Apr 15:annrheumdis-2020-217501. doi: 10.1136/annrheumdis-2020-217501. Epub ahead of print. PMID: 32295788.
15: Joob B, Wiwanitkit V. SLE, hydroxychloroquine and no SLE patients with covid-19: a comment. Ann Rheum Dis. 2020 Apr 15:annrheumdis-2020-217506. doi: 10.1136/annrheumdis-2020-217506. Epub ahead of print. PMID: 32295787.
16: Graef ER, Liew JW, Putman MS, Simard JF, Sirotich E, Berenbaum F, Duarte- García A, Grainger R, Harrison C, Konig MF, Korsten P, Proulx L, Richards DP, Robinson PC, Sattui SE, Ugarte-Gil MF, Young KJ, Kim AH, Sparks JA; COVID-19 Global Rheumatology Alliance. Festina lente: hydroxychloroquine, covid-19 and the role of the rheumatologist. Ann Rheum Dis. 2020 Apr 15:annrheumdis-2020-217480. doi: 10.1136/annrheumdis-2020-217480. Epub ahead of print. PMID: 32295786.
17: Mack HG. Hydroxychloroquine use during the COVID-19 pandemic 2020. Aust J Gen Pract. 2020 Apr 14;49. doi: 10.31128/AJGP-COVID-08. Epub ahead of print. PMID: 32294807.
18: Brufsky A. Hyperglycemia, Hydroxychloroquine, and the COVID-19 Epidemic. J Med Virol. 2020 Apr 15. doi: 10.1002/jmv.25887. Epub ahead of print. PMID: 32293710.
19: Zhang TY, Zhong B. Meeting the Potential Emergency Global Drug Supply Challenge of Hydroxychloroquine for COVID-19. Med Drug Discov. 2020 Apr 9:100036. doi: 10.1016/j.medidd.2020.100036. Epub ahead of print. PMID: 32292908; PMCID: PMC7144509.
20: Picot S, Marty A, Bienvenu AL, Blumberg LH, Dupouy-Camet J, Carnevale P, Kano S, Jones MK, Daniel-Ribeiro CT, Mas-Coma S. Coalition: Advocacy for prospective clinical trials to test the post-exposure potential of hydroxychloroquine against COVID-19. One Health. 2020 Apr 4:100131. doi: 10.1016/j.onehlt.2020.100131. Epub ahead of print. PMID: 32292817; PMCID: PMC7128742.
